Thomas Harth combines a dual master's background in bioengineering and applied economics with early-stage life sciences investing experience at Gimv in Antwerp, where he co-led investments in Anjarium Biosciences and Kinaset Therapeutics before joining Ysios in Barcelona. He tends to focus on companies with strong underlying science platforms, such as Tagworks' click-to-release chemistry and Memo Therapeutics' antibody discovery engine, and serves on both companies' boards while also speaking publicly on fundraising for cell and gene therapy startups.
About their Fund
Ysios Capital is Spain's largest life sciences venture capital firm, with ties to Spain's science leadership through cofounder Cristina Garmendia, who left the firm to serve as Spain's Minister of Science and Innovation before returning as a partner, and it has moved beyond typical venture investing into company creation through its InceptionBio vehicle, which builds biotech companies from early tech-transfer projects with a strong focus on Spain. The firm focuses on hard science areas like gene therapy, oncology, orphan CNS disease, calcification disorders, and regenerative cardiovascular implants, has backed deals such as Sanifit's acquisition by Vifor Pharma and U.S.-based Kala Pharmaceuticals, and produced three NASDAQ IPOs in 2021 alongside its oversubscribed €216M third fund.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































